{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-027611","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.109758+00:00","generated_at":"2026-06-06T05:52:35.512060+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya Therapeutics prices $50M public offering of 8.9M shares and pre-funded warrants at $4.50/share","bullets":["Gross proceeds expected ~$50M from 8,888,890 common shares at $4.50 and 2,222,271 pre-funded warrants at $4.499.","Offering includes participation from The Column Group, RA Capital, BlackRock, and other investors.","Expected to close February 12, 2024; Leerink Partners and TD Cowen are joint book-running managers.","Pre-funded warrants exercisable at $0.001 per share immediately until fully exercised."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-027611","json":"https://secwatch.observer/filing/0001193125-24-027611.json","markdown":"https://secwatch.observer/filing/0001193125-24-027611.md","text":"https://secwatch.observer/filing/0001193125-24-027611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312524027611/0001193125-24-027611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312524027611/d761271d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:52:35.512060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94e3b209d4ee629f14ea3eeb2779233fafe6edeb","claim":"Tenaya Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC, as representatives of the underwriters valued at approximately $50.0 million (effective 2024-02-07).","evidence_excerpt":"On February 7, 2024, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Offering”) of 8,888,890 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, at an offering price of $4.50 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,222,271 shares of the Company’s common stock at an offering price of $4.499 per underlying share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312524027611/0001193125-24-027611-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC and Cowen and Company, LLC, as representatives of the underwriters"},{"label":"Value","value":"approximately $50.0 million"},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}